Technical Data
Retinoblastoma, phosphorylated (Thr821) (Rb)
Retinoblastoma tumor suppressor protein (Rb) is associated with DNA binding activity and is thought to play a significant role in controlling cell cycle progression during tumor growth (1,2). Cell cycle-dependent phosphorylation by cdk’s inhibits Rb binding, thus allowing cell cycle progression (3). Rb inactivation and cell cycle progression likely requires first phosphorylation by cyclin D-cdk4/6 followed by cyclin E-cdk2 phosphorylation (4).

Suitable for use in Western Blot, Immunoprecipitation, and Immunocytochemistry. Other applications not tested.

Recommended Dilution:
Western Blot: 1:1000
Immunocytochemistry: 1:100
Immunoprecipitation: 1:20
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. For long-term storage, store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Manufactured incorporating RabMAb® technology under Epitomics US patents, No 5,675,063 and 7,429,487, owned by Abcam.
100ul -20°CBlue IceHumanRabbit
Synthetic phospho-peptide corresponding to residues surrounding Thr821 of human Rb
Supplied as a liquid in 50mM Tris-glycine pH 7.4, 0.15M NaCl, 0.01% sodium azide, 0.05% BSA, and 40% glycerol
Detects only human Rb phosphorylated on Threonine 821
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Lee, W.H., et al. The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 329: 642–5 (1987). 2. Sherr, C.J. Cancer cell cycles. Science 274: 1672–1677 (1996). 3. Knudsen, E.S. and J.Y. Wang. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol. Cell. Biol. 17: 5771–5783 (1997). 4. Lundberg, A.S. and R.A. Weinberg. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell. Biol. 18, 753–761 (1998).